Drugs / Pidotimod
Pidotimod
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04322669 | Aug → Nov 2021 | respiratory tract infectious disorder | Almirall, S.A. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pidotimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04322669 ↗ |
| Known as | NSC-759841 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1488165 ↗ |
| Known as | Pilimod | ChEMBL registry synonym — accepted as the source's own label CHEMBL1488165 ↗ |
| Modality | Small molecule | — CHEMBL1488165 ↗ |
| Route | Oral | “400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally” NCT04322669 ↗ |